Eluvixtamab

DB17252Investigational

Eluvixtamab: Overview.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain, Myeloid cell surface antigen CD33, and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: A cd33/cd3 bispecific t-cell engager antibody for acute myeloid leukemia therapy
Code names: AMG-330

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eluvixtamab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.